Blood pressure management is crucial for patients on veno-arterial extracorporeal membrane oxygenation (VA ECMO). Lower pressure can lead to end-organ malperfusion, whereas higher pressure may compete with ECMO flow and cardiac output. The impact of mean arterial pressure (MAP) on outcomes of patients on VA ECMO was evaluated. Patients who were supported on VA ECMO from September 2010 to March 2016 were retrospectively analyzed for average MAP throughout their course on ECMO, excluding the first and last day. Survival and complications observed during ECMO were investigated by classifying patients into groups based on their average MAP. A total of 116 patients were identified. Average MAP was significantly higher in patients who survived to discharge (82 ± 5.6 vs. 78 ± 5.5 mm Hg, p = 0.0003). There was a positive association between MAP and survival. Survival was best with MAP higher than 90 mm Hg (71%) and worst with MAP less than 70 mm Hg, where no patient survived. MAP was an independent predictor of survival to discharge by multivariate analysis (odds ratio 1.17, p = 0.013). Vasopressors were used more frequently in patients with lower pressure (coefficient -3.14, p = 0.005) without affecting survival (odds ratio 0.95, p = 0.95). Although the MAP did not affect the probability of strokes or bleeding complications, patients with a higher MAP had a lower incidence of kidney injury (p = 0.007). In conclusion, survival of patients on VA ECMO was significantly greater with a higher MAP, without being affected by prolonged vasopressor use.

Purpose: Accumulating evidence suggests that organs from ECMO patients can be safely transplanted after a declaration of cardiac or brain death. However, making a diagnosis of brain death while a patient is on ECMO poses unique challenges and limited literature exists. We sought to describe the practice variations involved with declaring patients brain dead on ECMO by reviewing charts from our local organ procurement organization.Methods: After institutional review board approval, a retrospective chart review from our local organ procurement organization was performed to identify patients declared brain dead on ECMO who became organ donors. Between 1995 and 2014, we identified 26 patients on ECMO who donated organs after being diagnosed with brain death. Demographics, causes of death, clinical and ancillary studies used to pronounce brain death were recorded from charts.Results: All patients underwent one to two clinical exams as the initial step in the declaration of brain death. In addition to clinical examination, 15 (58%) of the patients underwent apnea testing, and of those, seven (47%) also had at least one ancillary test performed. Apnea testing was not utilized in 11 (42%) of the patients, and of those, nine (82%) had one or more ancillary tests performed to confirm brain death. Two (18%) patients underwent clinical examination only. Seventy-five percent of patients from 1995 -2008 underwent apnea testing compared with only 50% of patients from 2009 to 2014.Conclusions: This study demonstrated the variability of practice patterns in the declaration of brain death for patients on ECMO over time and the lack of understanding of the CO2 physiology on ECMO. Additional studies are needed to devise a national standardized protocol to declare brain death on ECMO.

We present a 58-year-old female with a past history of a pituitary adenoma resected two years prior to admission who developed polymorphic ventricular tachycardia and cardiogenic shock requiring veno-arterial extracorporeal membrane oxygenation (VA-ECMO). We noted that the patient had stopped taking all of her medications six months prior to presentation. An extensive workup revealed acute panhypopituitarism with secondary hypothyroidism, secondary adrenal insufficiency, and central diabetes insipidus. She was immediately initiated on thyroid and adrenal hormone replacement therapy as well as fluid replacement. Within five days of her medical treatment, the patient’s cardiac function improved and she was successfully weaned from VA-ECMO and subsequently discharged home with appropriate hormone replacement therapy.